ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Artificial Intelligence
      • Beyond Basic Beta
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Direct Indexing
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Investing
      • ETF Education
      • ETF Strategist
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Institutional Income Strategies
      • Leveraged & Inverse
      • Managed Futures
      • Market Insights
      • Modern Alpha
      • Multifactor
      • Responsible Investing
      • Retirement Income
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Commodities
        • Gold/Silver/Critical Minerals
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. ETF Building Blocks Channel
  2. SBIO Rallied While Major Indexes Declined
ETF Building Blocks Channel
Share

SBIO Rallied While Major Indexes Declined

Elle CarusoOct 07, 2022
2022-10-07

The ALPS Medical Breakthroughs ETF (SBIO B-) rallied 3.66% last week, outpacing competing biotech ETFs and major U.S. indexes.

The biotech sector was propelled last week by long-awaited breakthrough Alzheimer’s trial data. Despite major macro headwinds for U.S. stocks, SBIO’s small- to mid-cap (SMID) biotech holdings that focus on later-stage drug trials continued to show their resilience and uncorrelated characteristics in a weak third quarter for U.S. markets, rising nearly 9% while the S&P 500 dipped nearly 5%, according to an October 3 insight from ALPS.

Biogen (BIIB, not in SBIO) last week released promising Phase III trial data for its Alzheimer’s immunotherapy that reduced cognitive decline by 27% in patients by inhibiting the production of amyloid plaque in the brain, once again putting the spotlight on the success of using immunotherapy antibodies to treat unmet medical diseases, according to ALPS. 

SBIO immunotherapy company, Prothena Corp Plc. (PRTA, 1.57% weight as of September 30), soared over 97% on the news, with its similar Alzheimer’s therapy expected to show results in 2023, ALPS wrote. Other immunotherapy companies in SBIO developing different treatments for cancer, rare and orphan diseases, neurology, cardiology, and hematology also rallied last week on the news.

“The biotech industry has made considerable headway in life-saving drug development since the pandemic, although these underlying catalysts have been muddied by lackluster stock returns as interest rates have risen over the past year,” ALPS wrote. 

FDA approvals for new chemical entities (leading to breakthrough immunotherapy drugs) saw 25% growth in 2021, outpacing year-over-year growth dating back to 2017, according to ALPS. 

That is expected to continue in 2022, highlighting the innovation through increasing research and development in biotech. The forthcoming approval of Biogen’s effective Alzheimer’s immunotherapy treatment, likely in January 2023, reflects a milestone for immunotherapy research, in which 87% of SBIO’s holdings utilize immunotherapy in their portfolio of treatments, according to ALPS.

Other biotech ETFs to consider include the SPDR S&P Biotech ETF (XBI A), the iShares Biotechnology ETF (IBB A-), and the First Trust NYSE Arca Biotechnology Index Fund (FBT C+).

For more news, information, and strategy, visit the ETF Building Blocks Channel.

vettafi.com is owned by VettaFi, which also owns the index provider for SBIO. VettaFi is not the sponsor of SBIO, but VettaFi’s affiliate receives an index licensing fee from the ETF sponsor.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X